

**Supplementary Table 1. Comparison of demographic and clinical characteristics between rheumatoid arthritis patients treated with isoniazid with and without liver function abnormality during follow-up**

Variable	Total (n = 96)	Liver function abnormality		p value
		Yes (n = 20)	No (n = 76)	
<b>Demographics and clinical characteristics</b>				
Age, yr	50.4 ± 10.8	50.9 ± 11.3	50.3 ± 10.7	0.83
Female sex	77 (80.2)	13 (65.0)	64 (84.2)	0.07
Disease duration, yr	8.5 ± 7.2	8.4 ± 5.8	8.6 ± 7.5	0.92
DAS28ESR(3)*	5.9 ± 0.9	6.3 ± 1.0	5.8 ± 0.8	0.04
BMI, kg/m <sup>2</sup>	22.0 ± 4.3	22.2 ± 3.1	21.9 ± 4.5	0.76
< 18.5	16 (16.7)	4 (20.0)	12 (15.8)	0.43
≥ 18.5 and < 23.0	36 (37.5)	5 (25.0)	31 (40.8)	0.43
≥ 23.0	44 (45.8)	11 (55.0)	33 (43.4)	0.43
Alcohol drinking	3/87 (3.5)	-	3/67 (4.5)	1.00
Smoking	10/87 (11.5)	2/20 (10.0)	8/67 (11.9)	1.00
Education, yr				0.90
≤ 9	28 (33.3)	7 (36.8)	21 (32.3)	
10–12	30 (35.7)	6 (31.6)	24 (36.9)	
> 12	26 (31.0)	6 (31.6)	20 (30.8)	
<b>Medication</b>				
No. of previous DMARDs used	4.1 ± 1.4	4.45 ± 1.3	4.1 ± 1.4	0.26
Months of TNF inhibitor use	21.8 ± 22.5	28.2 ± 25.5	20.1 ± 21.5	0.15
Type of TNF inhibitors				0.91
Infliximab	4 (4.2)	1 (5.0)	3 (4.0)	
Etanercept	66 (68.8)	13 (65.0)	53 (69.7)	
Adalimumab	26 (27.1)	6 (30.0)	20 (26.3)	
Concomitant use of corticosteroid	82 (85.4)	17 (85.0)	65 (85.5)	1.00
Concomitant use of methotrexate	83 (86.5)	16 (80.0)	67 (88.2)	0.46
Methotrexate dose, mg/wk	13.5 ± 2.8	12.7 ± 2.8	13.7 ± 2.8	0.21
Concomitant use of NSAIDs	79 (82.3)	14 (70.0)	65 (85.5)	0.18
Concomitant use of acetaminophen	28 (29.2)	7 (35.0)	21 (27.6)	0.71
<b>Comorbidity</b>				
Past history of hepatitis A	1 (1.0)	-	1 (1.3)	1.00
Past history of liver abnormality	5 (5.2)	1 (5.0)	4 (5.3)	1.00
Cardiovascular disease	-	-	-	
Pulmonary disease	3 (3.1)	1 (5.0)	2 (2.6)	0.51
Gastrointestinal disease	37 (38.5)	8 (40.0)	29 (38.2)	1.00
Diabetes mellitus	7 (7.3)	2 (10.0)	5 (6.6)	0.63
Malignancy	6 (6.3)	1 (5.0)	5 (6.6)	1.00

Values are presented as mean ± SD or number (%).

DAS, disease activity score; ESR, erythrocyte sedimentation rate; BMI, body mass index; DMARD, disease-modifying anti-rheumatic disease; TNF, tumor necrotizing factor; NSAID, nonsteroidal anti-inflammatory drug.